Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Apr 8;33(4):206–212. doi: 10.1002/clc.20732

Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel

Steen Husted 1,✉, Robert F Storey 2, Robert A Harrington 3, Håkan Emanuelsson 4, Christopher P Cannon 5
PMCID: PMC6653411  PMID: 20394040

Abstract

Background

Inflammation is a key factor in the development of atherosclerotic disease and acute coronary syndromes (ACS). The P2Y12 receptor antagonists ticagrelor (AZD6140) and clopidogrel may have anti‐inflammatory effects. The objective of this analysis from the Dose Confirmation Study Assessing Anti‐Platelet Effects of AZD6140 vs Clopidogrel in NSTEMI 2 (DISPERSE 2) trial was to compare ticagrelor and clopidogrel for effects on the inflammatory biomarkers C‐reactive protein (CRP), interleukin 6 (IL‐6), myeloperoxidase (MPO), and soluble CD40 ligand (sCD40L).

Hypothesis

Ticagrelor inhibits the P2Y12 receptor and inflammation to a greater extent than clopidogrel in nonST‐segment elevation ACS (NSTE‐ACS) patients.

Methods

In a double‐blind, double‐dummy, multicenter trial, 990 patients who had been hospitalized within the previous 48 hours with NSTE‐ACS were randomized to receive ticagrelor 90 mg twice daily, ticagrelor 180 mg twice daily, or clopidogrel 300 mg initially and then 75 mg once daily. Within the ticagrelor groups, patients were also randomized to receive or not receive a loading dose of ticagrelor 270 mg initially. All patients received standard treatment for ACS, which included 325 mg aspirin initially and 75 to 100 mg aspirin each day subsequently. Inflammatory biomarkers were measured at baseline, upon hospital discharge, and after 4 weeks.

Results

Inflammatory biomarker measurements were not significantly different among treatment groups at baseline, discharge, and 4 weeks.

Conclusions

Ticagrelor and clopidogrel appeared not to differ in this study with respect to the inflammatory biomarkers CRP, IL‐6, MPO, and sCD40L in patients with NSTE‐ACS. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (372.2 KB).

References

  • 1. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007; 65: S253–S259. [DOI] [PubMed] [Google Scholar]
  • 2. Lucas AR, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about acute coronary syndromes. Circulation 2006; 113: e728–e732. [DOI] [PubMed] [Google Scholar]
  • 3. Khuseyinova N, Koenig W. Biomarkers of outcome from cardiovascular disease. Curr Opin Crit Care 2006; 12: 412–419. [DOI] [PubMed] [Google Scholar]
  • 4. Tousoulis D, Antoniades C, Koumallos N, et al. Pro‐inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev 2006; 17: 225–233. [DOI] [PubMed] [Google Scholar]
  • 5. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes, part I: introduction and cytokines. Circulation 2006; 113: e72–e75. [DOI] [PubMed] [Google Scholar]
  • 6. Bisoendial RJ, Kastelein JJ, Peters SL, et al. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res 2007; 48: 952–960. [DOI] [PubMed] [Google Scholar]
  • 7. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001; 115: 3–12. [DOI] [PubMed] [Google Scholar]
  • 8. Schieffer B, Schieffer E, Hilfiker‐Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372–1378. [DOI] [PubMed] [Google Scholar]
  • 9. Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase‐generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999; 103: 1547–1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Parikh SV, de Lemos JA. Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci 2006; 332: 186–197. [DOI] [PubMed] [Google Scholar]
  • 11. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104–1111. [DOI] [PubMed] [Google Scholar]
  • 12. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)‐1Ra and IL‐6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in‐hospital coronary events. Circulation 1999; 99: 2079–2084. [DOI] [PubMed] [Google Scholar]
  • 13. Lee KW, Lip GY, Tayebjee M, et al. Circulating endothelial cells, von Willebrand factor, interleukin‐6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526–532. [DOI] [PubMed] [Google Scholar]
  • 14. Morrow DA, Rifai N, Antman EM, et al. C‐reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI IIA substudy. J Am Coll Cardiol 1998; 31: 1460–1465. [DOI] [PubMed] [Google Scholar]
  • 15. Scirica BM, Morrow DA, Cannon CP, et al. Clinical application of C‐reactive protein across the spectrum of acute coronary syndromes. Clin Chem 2007; 53: 1800–1807. [DOI] [PubMed] [Google Scholar]
  • 16. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440–1445. [DOI] [PubMed] [Google Scholar]
  • 17. Zairis MN, Adamopoulou EN, Manousakis SJ, et al; for the Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators. The impact of hs C‐reactive protein and other inflammatory biomarkers on long‐term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 2007; 194: 397–402. [DOI] [PubMed] [Google Scholar]
  • 18. Cavusoglu E, Ruwende C, Eng C, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007; 99: 1364–1368. [DOI] [PubMed] [Google Scholar]
  • 19. Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86: 649–655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049–1052. [DOI] [PubMed] [Google Scholar]
  • 21. Ruggeri ZM. Platelets in atherothrombosis. Nature Med 2002; 8: 1227–1234. [DOI] [PubMed] [Google Scholar]
  • 22. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006; 12: 1255–1259. [DOI] [PubMed] [Google Scholar]
  • 23.CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339. [DOI] [PubMed] [Google Scholar]
  • 24. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double‐blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–1047. [DOI] [PubMed] [Google Scholar]
  • 25. Woodward M, Lowe GD, Francis LM, et al. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C‐reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2004; 2: 1934–1940. [DOI] [PubMed] [Google Scholar]
  • 26. Chen YG, Xu F, Zhang Y, et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non–ST‐segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32–36. [PubMed] [Google Scholar]
  • 27. Azar RR, Kassab R, Zoghbi A, et al. Effects of clopidogrel on soluble CD40 ligand and on high‐sensitivity C‐reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151: 521.e1–521.e4. [DOI] [PubMed] [Google Scholar]
  • 28. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non–ST‐segment elevation acute coronary syndrome. J Am Coll Cardiol 2007; 50: 1844–1851. [DOI] [PubMed] [Google Scholar]
  • 29. Yusuf S, Zhao F, Mehta SR, et al; for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med 345: 494–502. [DOI] [PubMed] [Google Scholar]
  • 30. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852–1856. [DOI] [PubMed] [Google Scholar]
  • 31. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057. [DOI] [PubMed] [Google Scholar]
  • 32. Hartford M, Wiklund O, Mattsson Hultén L, et al. CRP, interleukin‐6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule‐1 during the early phase of acute coronary syndromes and long‐term follow‐up. Int J Cardiol 2006; 108: 55–62. [DOI] [PubMed] [Google Scholar]
  • 33. Palmerini T, Barozzi C, Tomasi L, et al. A randomised study comparing the antiplatelet and anti‐inflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST‐segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study. Thromb Res 2009; . doi:10.1016/j.thromres.2009.06.016. Available at: http://www.sciencedirect.com. [DOI] [PubMed] [Google Scholar]
  • 34. Wang J, Zhang S, Jin Y, et al. Elevated levels of platelet‐monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome. Int J Cardiol 2007; 115: 361–365. [DOI] [PubMed] [Google Scholar]
  • 35. Antonino MJ, Mahla E, Bliden KP, et al. Effect of long‐term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 2009; 103: 1546–1550. [DOI] [PubMed] [Google Scholar]
  • 36. Ivandic BT, Spanuth E, Haase D, et al. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem 2007; 53: 1231–1234. [DOI] [PubMed] [Google Scholar]
  • 37. Saw J, Madsen EH, Chan S, et al. The ELAPSE (Evaluation of Long‐Term Clopidogrel Antiplatelet and Systemic Anti‐Inflammatory Effects) study. J Am Coll Cardiol 2008; 52: 1826–1833. [DOI] [PubMed] [Google Scholar]
  • 38. Molero L, López‐Farré A, Mateos‐Cáceres PJ, et al. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol 2005; 146: 419–424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Pels K, Schwimmbeck PL, Rosenthal P, et al. Long‐term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor‐κβ and activator protein 1 activation in pigs. Eur J Clin Invest 2009; 39: 174–182. [DOI] [PubMed] [Google Scholar]
  • 40. Winning J, Reichel J, Eisenhut Y, et al. Anti‐platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009; 20: 50–57. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES